← Back to Clinical Trials
Recruiting NCT06477640

NCT06477640 Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06477640
Status Recruiting
Phase
Sponsor University of Rochester
Condition Pulmonary Arterial Hypertension PAH
Study Type INTERVENTIONAL
Enrollment 55 participants
Start Date 2024-07-29
Primary Completion 2026-12-31

Trial Parameters

Condition Pulmonary Arterial Hypertension PAH
Sponsor University of Rochester
Study Type INTERVENTIONAL
Phase N/A
Enrollment 55
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-29
Completion 2026-12-31
Interventions
ExerciseStandard of Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.

Eligibility Criteria

Inclusion Criteria: * Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic. * Adult patients (\>18 years old) with right heart catheterization confirmed pulmonary hypertension (PAH) on stable vasodilator dosing for at least 30 days. No planned titrations will occur during the 12-week study. If during the study, the treating physician feels it is necessary for safety reasons to adjust dosing, the subject will remain in their assigned group. * Access to a smart phone or email to receive daily messages. If patients do not have access to either, we will offer a smartphone with cellular service for use during the study to receive daily messages. * Clinically stable by the investigator (i.e., we will not enroll patients who endorse ongoing improvement or clinical worsening at enrollment). * The treating investigator (Dr. Lachant or Dr. White) will review the clinical data of an eligible patient and establish them as safe to participate prior to approaching the p

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology